Chugai Pharmaceutical Co., Ltd. (CHGCF) Research

Chugai Pharmaceutical Co., Ltd. is a Japan-headquartered global biopharmaceutical firm, engaged in the entire process of pharmaceutical product creation, from groundbreaking research and development to manufacturing, marketing, and worldwide distribution. Its extensive product portfolio targets critical health areas. In oncology, key offerings include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva. For osteoporosis, it provides Actemra, Edirol, and Bonviva. Other specialized medications address conditions such as erythropoiesis (Mircera) and secondary hyperparathyroidism (Oxarol). Furthermore, Chugai offers treatments like Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng for a range of other significant diseases. The company maintains a robust pipeline of development candidates, focusing on innovation across therapeutic fields including oncology, immunology, neuroscience, hematology, and ophthalmology. Founded in 1925 and based in Chuo, Japan, Chugai operates as a subsidiary of Roche Holding Ltd., cultivating strategic alliances with the Roche Group and fostering collaborative research initiatives with academic partners.

Market snapshot

Symbol
CHGCF
Price
$45.93
Day change
-3.88%
Market cap
$12.4T
P/E ratio
27.48x
52-week range
39.03-68.078
Sector
Healthcare
Industry
Drug Manufacturers - General
Next earnings
in 1 month

Peer companies

  • CSL Limited (CMXHF)
  • Daiichi Sankyo Company, Limited (DSKYF)
  • Daiichi Sankyo Company, Limited (DSNKY)
  • GSK plc (GLAXF)
  • HOYA Corporation (HOCPY)
  • Ipsen S.A. (IPSEY)
  • Merck KGaA (MKGAF)
  • Merck KGaA (MKKGY)

Open Chugai Pharmaceutical Co., Ltd. (CHGCF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.